apocell Home Contact Us

Illuminating biomarker detection – Leading the way in personalized medicine.

2016

Cancer Genetics, Inc. and ApoCell Announce Partnership Focused on Transforming Cancer Profiling and Therapy Selection Leveraging Proprietary, High-Performance Liquid Biopsy Platform for Rare Cell Capture and Detection

2015

Dr. Michael Gorin, M.D. from Johns Hopkins University Presents Proof of Concept Data Evaluating the Use of ApoStream® to Enrich Renal Cell Carcinoma CTCs

Liquid Biopsy Studies Using ApoStream® CTC Technology for Evaluating Patients With Breast Cancer or Renal Cell Carcinoma

Molecular Secrets of Breast Cancer Being Uncovered in BEACON Study

2014

Nektar Therapeutics’ Phase III BEACON Study Including ApoStream® Profiled in Targeted Oncology

ApoCell Mentioned in New York Times Article Discussing Liquid Biopsies

2013

ApoCell’s ApoStream® Technology Profiled by Xconomy

ApoCell Announces $1M SBIR Phase II Award for ApoStream® Development

ApoCell Announces European Expansion and Partnership with Fraunhofer Institute for Cell Therapy and Immunology (IZI)

ApoCell Named to Houston Business Journal’s Fast 100 for Third Consecutive Year

ApoCell and Transgenomic Present Results of Lung Cancer Research Study at the 2013 ASCO Annual Meeting

Nektar Therapeutics Presents Target-Specific Biomarker Data in ApoStream®-isolated Circulating Tumor Cells as part of the Phase III BEACON Study at the 2013 ASCO Annual Meeting

ApoCell Announces Delivery of First Prototypes of ApoStream® Circulating Tumor Cell (CTC) Isolation Device to National Cancer Institute

ApoCell and ApoStream® Discussed in Dow Jones VentureWire Article

2012

ApoStream® Featured in Biomicrofluidics Podcast

ApoCell Named to Deloitte’s Technology Fast 500

ApoCell Case Study: ApoStream® CTC Isolation Technology Being Used to Explore Biomarkers as Part of Phase III Global Study in Metastatic Breast Cancer

Beyond Counting Tumor Cells

ApoCell Technology Takes New Approach To Capturing Circulating Tumor Cells

New Technology Advances Cancer Detection Through Blood Testing

ApoCell’s Circulating Tumor Cell (CTC) Capture Technology First To Reliably Detect and Recover Deadly Liver Cancer Cells

New Technology Could Detect Liver Cancer from a Simple Blood Sample

2011

ApoCell Publishes Data Demonstrating the Improved CTC Capture Capabilities of the ApoStream® Device

ApoCell Awarded Phase I SBIR Grant

ApoCell Awarded $2.9 Million from SAIC-Frederick Inc.

ApoCell Launches Revolutionary Circulating Cancer Cell Detection System

Climbing the Informatics Mountain—It’s Not a Bubble: Highlights From the 2011 Tri-Conference

2009

Summit Partners Invests in ApoCell